Meeting
2013 ASCO Annual Meeting
Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study.
Authors
Eleftheria A Anastasopoulou
Cancer Immunology and Immunotherapy Center Saint Savas Cancer Hospital, Athens, Greece
Eleftheria A Anastasopoulou , Efi Pappou , Panagiotis Tzonis , Alexandros Ardavanis , Sathibalan Ponniah , Constantin N. Baxevanis , James L. Murray , Michael Papamichail , Sonia A. Perez , George Earl Peoples , Elizabeth Ann Mittendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3095)
DOI
10.1200/jco.2013.31.15_suppl.3095
Abstract #
3095
Poster Bd #
20F
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
First Author: Snehal Patel
Poster
2020 ASCO Virtual Scientific Program
A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).
First Author: Roisin Eilish O'Cearbhaill